Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIFEL-Trial: Epcoritamab + Ibrutinib in Refractory/Recurrent CNS Lymphoma
NCT07082868Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of epcoritamab in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) (3 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of dose limiting toxicities at 8 weeks. Started Aug 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT07082868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082868.